X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Witnessing a Historic Moment in U.S.-Japan Relations

By Guest Contributor  |    April 30, 2015
Masao Yoshida is the President and CEO of Astellas US LLC.Prime Minister Shinzo Abe addressed a Joint Session of Congress on Wednesday, April 29, 2015 at the U.S. Capitol.  It was a historic...   Read More

ICYMI: A Broad Coalition of Stakeholders Continue to Raise Concerns about Patent Litigation Reform

By Tina Stow  |    April 30, 2015
As we’ve shared here, here and here on the Catalyst, Congress is currently considering new patent litigation reform legislation. The Innovation Act (H.R. 9) will soon be marked up in the U.S....   Read More

World IP Day: The Foundation of Modern Life in America

By Mark Grayson  |    April 30, 2015
This week marks the celebration of  World Intellectual Property Day – an opportunity to reflect on and highlight the many ways that patents and trademarks serve as the very foundation of modern...   Read More

Ask About Adherence: Q&A with PhRMA Foundation Young Investigator Adherence Grantee - Sujit S. Sansgiry

By Samantha Dougherty  |    April 30, 2015
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Sujit S. Sansgiry, PhD, a 2015 PhRMA Foundation Young Investigator Adherence...   Read More

What They Are Saying: Close Patent Loopholes That Threaten Innovation for Patients

By Robert Zirkelbach  |    April 29, 2015
“When we developed these proceedings, we never thought people would use them this way” -  Former general counsel of the PTO New administrative proceedings at the Patent and Trademark Office...   Read More

Prime Minister Abe’s Visit is an Important Step Toward Strengthening Innovation

By Jay Taylor  |    April 29, 2015
Today was an historic day for Japanese Prime Minister Shinzo Abe, who arrived in the U.S. on Sunday for a week-long visit and became the first Japanese leader to address a joint session of...   Read More

ICYMI: 340B Program Raises Eyebrows in North Carolina

By Allyson Funk  |    April 28, 2015
In case you missed it, a recent article in The Charlotte Observer spotlights new revelations about the 340B drug discount program in North Carolina. An inquiry by Senator Chuck Grassley (R-Iowa)...   Read More

Three Things You Need to Know about Today's WSJ Story on Medicine Prices

By Holly Campbell  |    April 27, 2015
In case you missed it, a Wall Street Journal article this morning explored pricing trends in the biopharmaceutical industry. In the piece, the authors correctly stated that spending on retail...   Read More

Patients: They're at the Table – It’s About Time to Ask Them What Should be Served

By Guest Contributor  |    April 27, 2015
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Medicare Monday: What You Need To Know About Part D Appeals

By Allyson Funk  |    April 27, 2015
Did you know there is a process in Medicare Part D to appeal a coverage decision made by your plan about a medicine you need? Meaning, if a beneficiary is told at the pharmacy counter that his or...   Read More

Why Cross-Country Comparisons on Drug Prices are Misleading

By Robert Zirkelbach  |    April 24, 2015
Too often, critics greatly exaggerate price differences between the U.S. and other countries to create an erroneous impression that medicines are a major driver of U.S. health care cost growth –...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Patients Treating Mental Health Conditions

By Allyson Funk  |    April 24, 2015
We’ve been exploring profiles of patients managing different chronic conditions like cancer and rheumatoid arthritis and the burdensome out-of-pocket costs they face. Unfortunately, for many like...   Read More

What They Are Saying: Stakeholders Raise Concerns about Patent Litigation Reform

By Robert Zirkelbach  |    April 24, 2015
Patents are critical to the innovation ecosystem, and the lifeblood of the biopharmaceutical industry. Protecting and enforcing them is essential to keeping the engine of scientific discovery...   Read More

Ask About Adherence: PhRMA Foundation Young Investigator Adherence Grant Program

By Samantha Dougherty  |    April 23, 2015
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. But, this week we are straying from our regular format to announce that the PhRMA Foundation has awarded...   Read More

ICYMI – Cancer Leaders Lay Out Policy Road Map for Continued Progress

By Holly Campbell  |    April 23, 2015
In case you missed it, a special report, “Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care,” published online yesterday in the American Association for Cancer Research...   Read More

Earth Day 2015: Green Initiatives are Good for Business and the Environment

By Anne McDonald Pritchett, PhD  |    April 22, 2015
Earth Day provides us all with an opportunity to consider the role each of us can play in protecting the Earth’s natural resources. The nation’s innovative biopharmaceutical companies spend...   Read More

What You Need to Know about the New Kaiser Poll

By Robert Zirkelbach  |    April 22, 2015
Spending on retail prescription medicines has consistently accounted for just 10 percent of health care spending, even though biopharmaceutical companies have brought more than 500 medicines to...   Read More

PhRMA Member Companies Invested $51.2 Billion in R&D in 2014

By John Castellani  |    April 20, 2015
Earlier today, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced that its member companies have invested more than $600 billion in the search for new treatments and cures...   Read More

Continuing and Expanding the Georgetown-PhRMA Fellowship Program

By Guest Contributor  |    April 20, 2015
This is an exciting time for biomedical research as innovation is at an all-time high. To continue this positive trajectory, researchers need training opportunities that embrace team science...   Read More

Medicare Monday: Medication Therapy Management in Part D – Another Potential Opportunity for Savings

By Allyson Funk  |    April 20, 2015
Over the past few weeks, we’ve discussed how Medicare Part D helps patients with a number of different conditions including Parkinson’s, artery plaque, congestive heart failure, chronic...   Read More

Week in Review: The Latest from PhRMA

By Tina Stow  |    April 17, 2015
Spending on Medicines: The Big Picture – PhRMA’s new video explains how high generic utilization rates, competition among brand-name medicines and aggressive tactics by insurers and pharmacy...   Read More

ICYMI: Has the 340B Program Lost Its Way?

By Allyson Funk  |    April 16, 2015
In case you missed it, an article in the latest issue of Managed Care Magazine explores the 340B drug discount program. Columnist Richard Kirkner calls 340B a “well-intended program [that] has...   Read More

Spending on Medicines: The Big Picture

By Holly Campbell  |    April 16, 2015
There has been a lot of discussion lately on spending on prescription medicines. And too often this dialogue fails to acknowledge that retail prescription medicines have consistently accounted for...   Read More

Paying for Personalized Medicine: Protecting the Future of Patient-Centered Cancer Care

By Guest Contributor  |    April 15, 2015
At a time of unprecedented scientific breakthroughs in oncology, personalized medicine is enabling more accurate diagnoses and more targeted treatments, increasing the overall efficiency and...   Read More

How a Competitive Biopharmaceutical Marketplace Helps to Control Costs

By Robert Zirkelbach  |    April 14, 2015
Too often conversations on the cost of medicines fail to acknowledge the competitive biopharmaceutical market that exists in the U.S., which helps to control costs while encouraging the...   Read More

Putting 2014 Figures on Prescription Drug Spending in Context

By Lori Reilly  |    April 14, 2015
Last year was unique for our nation’s health care system. Nearly 10 million uninsured patients gained health insurance coverage – the largest gain in four decades -- and the FDA’s Center for Drug...   Read More

Medicare Monday: How Part D Helps Parkinson’s Patients

By Allyson Funk  |    April 13, 2015
We often talk about the importance of adherence on The Catalyst, but it’s a topic that isn’t widely understood. Consider this: when patients prematurely discontinue their medication, it costs the...   Read More

Week in Review: The Latest from PhRMA

By Mollymae Metheny  |    April 10, 2015
The reality of prescription drug spending in Medicaid, more than 240 Medicines in Development to treat blood cancers, PPA celebrates its 10th anniversary, look at a patient with rheumatoid...   Read More

PhRMA & LLS: More than 240 Medicines in Development for Blood Cancers

By Tina Stow  |    April 10, 2015
It’s hard to believe, but – this year alone – more than 162,000 Americans will be diagnosed with a form of blood cancer, such as leukemia, lymphoma or myeloma. Fortunately, science has advanced...   Read More

The Reality of Prescription Drug Spending in Medicaid

By Robert Zirkelbach  |    April 9, 2015
Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S.,...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Rheumatoid Arthritis Patient

By Allyson Funk  |    April 9, 2015
Last month, we walked through how managing chronic myeloid leukemia with a health insurance exchange plan can leave patients with burdensome out-of-pocket costs and put patients’ access to...   Read More

Ask About Adherence: Q&A with Pharmacy Quality Alliance

By Samantha Dougherty  |    April 9, 2015
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Laura Cranston, Pharmacy Quality Alliance (PQA) executive director, on...   Read More

Paving the Way for Better Cancer Treatments

By Randy Burkholder  |    April 8, 2015
Last week, during Ken Burns’ documentary, Cancer: The Emperor of All Maladies, Americans heard about the scientific community’s decades-long, tireless fight to treat and cure cancer, an incredibly...   Read More

Partnership for Prescription Assistance Celebrates 10th Anniversary

By Holly Campbell  |    April 7, 2015
This week the Partnership for Prescription Assistance (PPA) celebrates its 10th anniversary of connecting uninsured or underinsured Americans to programs that provide prescription medicines for...   Read More

Medicare Monday: Medicare Part D Helps Reduce Spending in Parts A and B, Too

By Allyson Funk  |    April 6, 2015
Last week, we talked about how Medicare Part D helps seniors live better by facilitating access to needed medicines and helping to avoid the use of more costly medical services. What we didn’t...   Read More

Progress to Improve Patient Lives - A Review

By Christian Clymer  |    April 3, 2015
Almost three years ago, PhRMA President and CEO John Castellani wrote a Catalyst post highlighting the evolution of the fight against cancer. He concluded that to advance progress, stakeholders...   Read More

ICYMI – WSJ: The Arrow of U.S. Cancer Progress

By Holly Campbell  |    April 3, 2015
In case you missed it, The Wall Street Journal editorial team published an opinion piece yesterday online and in today’s print edition on the progress biopharmaceutical research companies have...   Read More

Week in Review: The Latest from PhRMA

By Mollymae Metheny  |    April 3, 2015
Communications with health care professionals, advances in cancer treatment documentary, importance of safe drug disposal and more Communications with Health Care Professionals – Mit Spears, Jeff...   Read More

The Vital Role of Clinical Outcome Assessments in Patient-Centered Drug Development

By Gabriela Lavezzari  |    April 3, 2015
The Food and Drug Administration (FDA) Public Workshop on Clinical Outcomes Assessment Development and Implementation: Opportunities and Challenges, held earlier this week, was an important...   Read More

340B Paradox: As the Uninsured Rate Drops, 340B Program Continues to Grow

By Karyn Schwartz  |    April 2, 2015
Recent studies show the Affordable Care Act (ACA) has reduced the uninsured rate and lowered the amount of uncompensated care that hospitals provide. Paradoxically, these welcome trends are also...   Read More

3 Reasons Patient Engagement is the Backbone of Scientific Discovery

By Michelle Nyman  |    April 1, 2015
Each year, the National Health Council (NHC) convenes the Voluntary Health Leadership Conference (VHLC) – a forum that brings together patient advocacy organizations to share information about the...   Read More

Embracing 21st Century Information Sharing: Defining a New Paradigm for the FDA and Communications with Health Care Professionals

By Mit Spears  |    April 1, 2015
The Food and Drug Administration (FDA) protects public health by approving new medicines for patients, ensuring unsafe treatments are not used and monitoring the evolution of scientific insights...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates